Environmental and genetic factors influencing inhibitor development.
about
Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations.T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsIncreased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIIIMild hemophilia A.Eighteen years of molecular genotyping the hemophilia inversion hotspot: from southern blot to inverse shifting-PCR.Inhibitors in congenital coagulation disorders.Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.Genetic diagnosis of haemophilia and other inherited bleeding disorders.Genetic risk factors for inhibitors to factors VIII and IX.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Haemophilia A: molecular insights.Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicityInfluence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A miceThe use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Inhibitors of factor VIII in black patients with hemophiliaClinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Inherited disorders of blood coagulation.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceFormation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?The role of previously untreated patient studies in understanding the development of FVIII inhibitors.Factor VIII haplotypes frequencies in Tunisian hemophiliacs AIn non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Late immune tolerance induction in haemophilia A patients.Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.A retrospective postlicensure survey of FEIBA efficacy and safety.Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.Heterozygous large deletions of Factor 8 gene in females identified by multiplex PCR-LC.Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
P2860
Q30403462-678F67F0-3EE0-483F-A024-B308AA6DECEFQ30620098-F67F41F5-F511-46C1-9DD2-D41BEC12F36DQ31098999-C3360255-CEC0-48FC-879F-86C73548AE19Q33910694-BD6CD9F5-931F-4B3A-A710-AFC58BB6F473Q34025098-1659B386-E356-4FA2-A1EB-61BFED42C5C6Q34110768-92FDDB74-FC73-48FB-AE5A-A6736FBCFB92Q34129239-0879565E-96AC-4105-BCF2-0E91D46D0CF6Q34550081-EA48C1F3-6839-4EC8-A779-232189787055Q34614695-C87812F6-B585-4D33-ADED-9F61FF1EE8BFQ35536115-BA09D372-A9DD-432B-B245-28594E67B9BBQ35937076-1D6400FB-7E09-4736-A4C4-E578BEB193B4Q36473047-B367A963-E3B7-42F6-9BF3-FE0E525D219BQ36473065-16648846-92F6-41F1-BC8B-61ADBD79CFD8Q36661811-4610CE34-B8D2-4398-8D78-F670DC75583BQ36707550-E8875247-8B97-44E2-A59A-77DBF89F9AD8Q36793856-BE4124F6-9E91-44B5-AB48-F23CD2862EB7Q36950922-783E3E0F-151E-447D-BE37-259B677622F9Q36951646-E8CC95A6-119D-4514-AB72-991EF756ECEBQ37032857-19523042-D617-4C85-97FC-5236D12F9516Q37176534-8CD8A1A6-4BD4-4A97-94FB-1360EA09C512Q37385316-23DAC736-A304-4C83-B76B-9F9D97F42384Q37700537-52F54F23-E871-4407-A79B-956BDE6408A7Q37876411-0555DB74-5CF8-4941-97D9-A7BE3C474513Q38101041-8B8F6BE0-E8F2-4150-899C-FE19E3B5CB79Q38202541-6C53F787-BF30-4177-9CF2-7F734652CC78Q38537167-05B03D35-8766-4076-B298-B944EA2AE113Q38575475-FB9B9F58-160C-45CC-8E1C-AFC2C34DFCD2Q38992151-4B82A697-668E-42C6-83FC-1505D6E0210CQ39463597-CABAEF0E-D355-44C5-87AE-22212522A0FFQ44853253-7BB74D69-7629-4B09-9BBA-74B6B012D647Q45855110-5E6C5C6B-A861-4CF5-BA1B-FD3458982AD7Q45859618-55C82289-3508-4716-82F0-3076E13732C5Q45865338-2E16079A-0C3D-46A4-8ABF-310463C586A4Q45865800-39BFFD01-B36F-4ED9-86DF-C0793EA06E08Q45866554-E5494474-45C2-45C1-ADA3-C7A08C655FBCQ45868068-F4B944D8-AA8D-4985-AD03-BA06998F3B32Q45871996-2A9DE428-4132-4CB4-921E-70C74CD3BD8BQ45872129-4AC5F873-CF02-4590-AE8A-BF202F46F7F6Q45874698-0E4C0396-6D8C-4AF3-A82E-17A41436DD3EQ45875555-DD6A1E37-567E-4131-9221-657A2550C2AE
P2860
Environmental and genetic factors influencing inhibitor development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Environmental and genetic factors influencing inhibitor development.
@ast
Environmental and genetic factors influencing inhibitor development.
@en
type
label
Environmental and genetic factors influencing inhibitor development.
@ast
Environmental and genetic factors influencing inhibitor development.
@en
prefLabel
Environmental and genetic factors influencing inhibitor development.
@ast
Environmental and genetic factors influencing inhibitor development.
@en
P2093
P1476
Environmental and genetic factors influencing inhibitor development.
@en
P2093
Clemens Müller-Reible
Edward Tuddenham
Hans Hermann Brackmann
Johannes Oldenburg
Jörg Schröder
Rainer Schwaab
P356
10.1053/J.SEMINHEMATOL.2003.11.016
P433
P577
2004-01-01T00:00:00Z